AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

12 июл 2023 06:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

07 июл 2023 06:00:53 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

30 июн 2023 15:02:39 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

28 июн 2023 08:28:25 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

27 июн 2023 19:24:44 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

01 июн 2023 06:00:30 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

30 май 2023 06:00:54 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

08 май 2023 06:00:16 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

03 май 2023 06:00:50 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

01 май 2023 06:00:31 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

21 апр 2023 06:00:34 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

14 апр 2023 06:00:49 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

13 апр 2023 06:00:34 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 мар 2023 06:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 фев 2023 06:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

22 фев 2023 06:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 06:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

31 янв 2023 06:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

07 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

28 ноя 2022 05:35:00 Источник Nasdaq GlobeNewswire